| Study | Reason for exclusion |
|---|---|
| Albers 2016 | Post‐hoc analysis of observational study |
| Albers 2020 | Data pooled from 2 studies, also post hoc analysis looking at participants grouped by prior omalizumab use, which is not a subgroup prespecified in our protocol |
| Alvarez‐Cuesta 1994 | Intervention used in study (cat extract immunotherapy) is not anti‐IL‐5 therapy |
| Armentia 1992 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| Austin 2016 | Aggregation of 2 clinical trials |
| Austin 2016a | Not an RCT (analysis of the characteristics of patients that entered 2 trials of mepolizumab) |
| Ayres 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Bardford 2018 | Post hoc analysis of mepolizumab study (MUSCA, Chupp 2017), looking at participants grouped by prior omalizumab use, which is not a subgroup prespecified in our protocol. |
| Bel 2014 | Focus of trial is on steroid reduction and therefore does not meet our predefined inclusion criteria |
| Berger 2003 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Bernstein 2020a | Not asthma (wrong disease group) |
| Bjermer 2017 | Only pooled data (from > 1 RCT) presented |
| Blanken 2012 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Blanken 2013 | Intervention used in study (pavilizumab) is not anti‐IL‐5 therapy |
| Bleecker 2018a | Data pooled from 2 studies |
| Bleecker 2018b | Only pooled data (from > 1 RCT) presented |
| Boulet 1997 | Intervention used in study (anti‐IgE antibody e25) is not anti‐IL‐5 therapy |
| Bourdin 2018 | Post hoc analysis of reslizumab study looking at patients grouped by presence or absence of allergen‐specific IgE, which is not a subgroup prespecified in our protocol. |
| Bourdin 2020 | This is not an RCT (it is a type of meta‐analysis of other RCTs) |
| Bousquet 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Bousquet 2011 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Brightling 2014 | Intervention used in study (tralokinumab) is not anti‐IL‐5 therapy |
| Brown 2007 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Brusselle 2016 | Aggregation of 2 clinical trials |
| Brusselle 2017 | Data pooled from 2 studies, also post hoc analysis looking at participants grouped by baseline step 4/5 therapy, which is not a subgroup prespecified in our protocol. |
| Bryant 1975a | Not a RCT |
| Bryant 1975b | Not a RCT |
| Buhl 2000a | Intervention used in study (rhumab‐25) is not anti‐IL‐5 therapy |
| Buhl 2000b | Intervention used in study (rhumab‐25) is not anti‐IL‐5 therapy |
| Buhl 2002 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Bush 1985 | Intervention used in study (soybean oil) is not anti‐IL‐5 therapy |
| Busse 2001 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Busse 2008 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Busse 2015 | Intervention used in study (tralokinumab) is not anti‐IL‐5 therapy |
| Buttner 2003 | Treatment < 16 weeks |
| Caffarelli 2000 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| Canvin 2016 | Aggregation of 2 clinical trials |
| Carr 2017 | Data pooled from 2 studies |
| Carr 2019 | Only pooled data (from > 1 RCT) presented |
| Castro 2011 | < 16 weeks in length |
| Castro 2014 | Intervention used in study (dupilumab) is not anti‐IL‐5 therapy |
| Castro 2018 | Data pooled from 2 studies, also post hoc analysis looking at participants grouped by whether screening and baseline eosinophils > 400 or not, which is not a subgroup prespecified in our protocol |
| Chandra 1989 | Intervention used in study (various foods) is not anti‐IL‐5 therapy |
| Chanez 2017 | Only pooled data (from > 1 RCT) presented |
| Chanez 2017a | Only pooled data (from > 1 RCT) presented |
| Chanez 2018 | Open‐label extension not an RCT |
| Chanez 2019 | Post hoc analysis of reslizumab study comparing participants who didn’t have a blood eosinophil response to reslizumab to those who did, which is not a subgroup prespecified in our analysis |
| Chauhan 2017 | Only pooled data (from > 1 RCT) presented |
| Chervinsky 2003 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Chipps 2017 | Pooled data only (from SIROCCO (Bleecker 2016) and CALIMA FitzGerald 2016) studies; data are already in the analysis) |
| Chipps 2018 | Only pooled data (from > 1 RCT) presented |
| Chipps 2019 | Only pooled data (from > 1 RCT) presented |
| Chipps 2020 | Only pooled data (from > 1 RCT) presented |
| Clavel 1998 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| Corren 2003 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Corren 2010 | Intervention used in study (il‐4r alpha antagonist) is not anti‐IL‐5 therapy |
| Cullell‐Young 2002 | Not a RCT |
| Dasgupta 2016 | Participants did not have a diagnosis of asthma (COPD patients) |
| De Boever 2014 | Intervention used in study (anti‐IL‐13 mab) is not anti‐IL‐5 therapy |
| Djukanovic 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| DuBuske 2018 | Data pooled from 2 studies |
| Ebner 1989 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| Eckman 2010 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| El‐Nawawy 2000 | Not a RCT |
| EUCTR2012‐004385‐17‐BE | The study participants did not have asthma |
| EUCTR2015‐001152‐29‐BE | Not an RCT and endpoints are not applicable as this is a long‐term access programme |
| EUCTR2016‐001831‐10‐NL | No placebo arm/single treatment arm and treatment duration < 16 weeks |
| EUCTR2016‐002405‐19‐DE | Participants do not have a diagnosis of asthma, no placebo arm, treatment duration < 16 weeks |
| EUCTR2017‐003958‐16‐NL | Treatment duration < 16 weeks (12 weeks) |
| Fahy 1997 | Intervention used in study (anti‐IgE) is not anti‐IL‐5 therapy |
| Fahy 1999 | Intervention used in study (anti‐IgE) is not anti‐IL‐5 therapy |
| Ferguson 2016a | Benralizumab for mild to moderate, persistent asthma: the BISE phase III study ‐ duration < 16 weeks (12 weeks) |
| Ferguson 2016b | Treatment duration < 16 weeks in length |
| Ferguson 2017 | Study duration < 16 weeks (12 weeks) |
| Finn 2003 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| FitzGerald 2017a | Post hoc analysis of CALIMA (FitzGerald 2016), benralizumab study looking at the subset of patients from Japan, which is not a subgroup prespecified in our protocol. |
| FitzGerald 2017b | Only pooled data (from > 1 RCT) presented |
| FitzGerald 2018 | Only pooled data (from > 1 RCT) presented |
| Fitzgerald 2019 | 2‐year safety study including 1 year in RCT (3 studies pooled) and 1 year open‐label extension |
| Flood‐Page 2003 | Treatment < 16 weeks |
| Flood‐Page 2007 | Treatment < 16 weeks |
| Frew 1998 | Intervention used in study (anti‐IgE) is not anti‐IL‐5 therapy |
| Garcia 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Garin 2019 | Only pooled data (from > 1 RCT) presented |
| Gauvreau 2011 | Intervention used in study ( anti‐IL‐13) is not anti‐IL‐5 therapy |
| Gauvreau 2014a | Intervention used in study (quilizumab) is not anti‐IL‐5 therapy |
| Gauvreau 2014b | Intervention used in study (anti‐tslp) is not anti‐IL‐5 therapy |
| Gauvreau 2014c | Intervention used in study (OX40L antagonist) is not anti‐IL‐5 therapy |
| Gauvreau 2015a | Intervention used in study (ligelizumab) is not anti‐IL‐5 therapy |
| Gauvreau 2015b | Intervention used in study (ligelizumab) is not anti‐IL‐5 therapy |
| Gevaert 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Gibson 2021 | Wrong study design |
| Goldman 2017 | Only pooled data (from > 1 RCT) presented |
| Gopalan 2017a | Data pooled from 2 studies |
| Gopalan 2017b | Data pooled from 2 studies |
| Gordon 1972 | Intervention used in study is not anti‐IL‐5 therapy |
| Greenberg 1991 | Participants do not have a diagnosis of asthma |
| Gunsoy 2016 | Not a randomised, placebo‐controlled trial |
| Han 2009 | Intervention used in study (jade screen powder) is not anti‐IL‐5 therapy |
| Hanania 2011 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Hanania 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Hanania 2014 | Intervention used in study (lebrikizumab) is not anti‐IL‐5 therapy |
| Hanania 2015 | Intervention used in study (lebrikizumab) is not anti‐IL‐5 therapy |
| Harris 2016 | Intervention used in study (quilizumab) is not anti‐IL‐5 therapy |
| Hendeles 2015 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Hickey 2019 | Only pooled data (from > 1 RCT) presented |
| Hill 1982 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| Hodsman 2013 | Intervention used in study ( anti‐IL‐13) is not anti‐IL‐5 therapy |
| Holgate 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Hoshino 2012 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Howarth 2020 | Study focused on nasal polyps rather than asthma |
| Humbert 2005 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Humbert 2008 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Humbert 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Humbert 2017 | Post hoc analysis looking at participants in a reslizumab trial (BREATH) grouped by omalizumab eligibility, which is not a subgroup prespecified in our protocol |
| Humbert 2019 | Data pooled from 2 mepolizumab studies (MENSA, MUSCA), post hoc analysis looking at participants grouped by omalizumab eligibility, which is not a subgroup prespecified in our protocol |
| Iino 2019 | Study in eosinophilic otitis media not asthma |
| Jackson 2019 | Pooled data only from trials that are already included (Bleecker 2016; FitzGerald 2016) |
| Jacobs 2018 | Pooled data only from trials that are already included (Castro 2015a; Castro 2015b) |
| Jacquemin 1995 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| Jimenez 2019 | Aggregation of 5 studies |
| Jutel 2005 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| Kang 1988 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| Katial 2019 | Subgroup analysis by subgroups not relevant to our protocol |
| Katial 2020 | Post hoc analysis of benralizumab study looking at patients grouped by high or low FeNO, which is not a subgroup prespecified in our protocol |
| Kim 2020 | Pooled data only: mepolizumab IV (Pavord 2012a), and mepolizumab SC (Ortega 2014) |
| Kips 2003 | Treatment < 16 weeks |
| Kon 2001 | Intervention used in study (anti‐cd4) is not anti‐IL‐5 therapy |
| Kopp 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Kopp 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Korenblat 2018 | Only pooled data (from > 1 RCT) presented |
| Kreindler 2019 | Pooled data only from trials that are already included (Bleecker 2016; FitzGerald 2016) |
| Kuang 2018 | Not asthma (hypereosinophilic syndrome) |
| Kuang 2019 | Not asthma (hypereosinophilic syndrome) |
| Kulus 2010 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Lam 2018 | Not a RCT (cost‐effectiveness analysis incorporating multiple inputs, including but not only data from 2 RCTs) |
| Lanier 2003 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Lanier 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Laviolette 2013 | Treatment < 16 weeks |
| Leckie 2000 | Treatment < 16 weeks |
| Leynadier 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Li 2016 | Review article, not a RCT |
| Lizaso 2008 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| Lugogo 2016 | Not a randomised, placebo‐controlled trial |
| Lugogo 2020 | The intervention includes a reduction in standard asthma management (OCS maintenance), and as per our protocol, we have excluded such studies as the heterogeneity in study design makes them too dissimilar to compare |
| Manning 2018 | Only pooled data (from > 1 RCT) presented |
| Maselli 2017 | Trial involves OCS dose reduction (1 of our exclusion criteria) |
| Maspero 2016 | Combined secondary analysis of 2 trials |
| Maspero 2018 | Pooled data from 2 trials (Bleecker 2016; FitzGerald 2016) |
| Maspero 2019 | Only pooled data (from > 1 RCT) presented |
| Massanari 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Massanari 2010 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Mathur 2019 | Pooled data from 2 trials (Bleecker 2016; FitzGerald 2016) |
| Mathur 2020 | Only pooled data (from > 1 RCT) presented |
| Maunoury 2018 | Not a RCT |
| Menzies‐Gow 2019a | Trial involves OCS dose reduction (one of our exclusion criteria) |
| Menzies‐Gow 2019b | Trial involves OCS dose reduction (one of our exclusion criteria) |
| Metzger 1998 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Milgrom 1999 | Intervention used in study (anti‐IgE) is not anti‐IL‐5 therapy |
| Milgrom 2001 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Modlin 1977 | Participants do not have diagnosis of asthma |
| Moran 2020 | Not an RCT (observational study of patients with asthma and COPD) |
| Moss 1987 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| Murphy 2018 | Only pooled data (from > 1 RCT) presented |
| Nair 2009 | Focus of trial is on steroid reduction and therefore does not meet our predefined inclusion criteria |
| Nair 2016 | All participants do not have a diagnosis of asthma |
| Nair 2017a | Trial involves OCS dose reduction (1 of our exclusion criteria) |
| Nair 2017b | Substudy of a trial involving OCS dose reduction (one of our exclusion criteria) |
| Nair 2017c | Trial involves OCS dose reduction (one of our exclusion criteria) |
| Nair 2020 | Only pooled data (from > 1 RCT) presented |
| NCT00783289 | Treatment duration < 16 weeks |
| NCT00802438 | Not RCT |
| NCT01290887 | Study does not include a placebo arm |
| NCT01366521 | Phase 2 study comparing three doses of mepolizumab. This trial does not have a placebo arm. |
| NCT01471327 | Focus of study was on tolerability, pharmacokinetics and pharmacodynamics of single dose SB‐240563 administered IV to Japanese healthy male participants. People with asthma were not included in the study. |
| NCT01520051 | Duration < 16 weeks, additional intervention (experimental rhinovirus infection) |
| NCT01691859 | This study does not include a placebo group. Multi‐centre, open‐label, long‐term safety study with total sample receiving 100 mg mepolizumab administered SC (no control group) |
| NCT01842607 | This study does not include a placebo group. Multi‐centre, open‐label, long‐term safety study with total sample receiving 100 mg mepolizumab administered SC (no control group) |
| NCT02020889 | The study participants did not have asthma |
| NCT02075255 | Focus of trial is on oral steroid reduction |
| NCT02135692 | This study does not include a placebo group. Multi‐centre, open‐label, long‐term study of SC administered mepolizumab 100 mg in addition to standard care, in participants with severe eosinophilic asthma |
| NCT02258542 | Not a RCT (an extension study with no placebo arm) |
| NCT02293265 | Aim of study is to provide a "reliable description of the severe asthma patient landscape with respect to the potential eligibility for treatment with mepolizumab, omalizumab, and reslizumab". No pharmaceutical intervention in study |
| NCT02377427 | Treatment period < 16 weeks |
| NCT02417961 | Not a RCT |
| NCT02501629 | Focus of trial is on oral steroid reduction |
| NCT02559791 | Not placebo‐controlled ‐ single treatment arm only |
| NCT02594332 | Study terminated (recruitment problems) |
| NCT02654145 | Not placebo‐controlled. Single treatment arm only |
| NCT02808819 | Not an RCT |
| NCT02814643 | Treatment duration < 16 weeks |
| NCT02821416 | Duration < 16 weeks, additional intervention (allergen challenge) |
| NCT02869438 | Treatment duration < 16 weeks |
| NCT02937168 | Treatment duration < 16 weeks |
| NCT02968914 | Not a placebo‐controlled trial |
| NCT03014674 | Not a placebo‐controlled trial and treatment duration < 16 weeks |
| NCT03021304 | No placebo arm/single treatment arm, treatment duration < 16 weeks |
| NCT03476109 | No placebo comparator |
| NCT04617171 | Treatment of participants with acute asthma exacerbation, not chronic asthma |
| NCT04710134 | Ineligble study design |
| Nelsen 2019 | Pooled data from 2 trials (Chupp 2017; Ortega 2014), and a 3rd observational study |
| Newbold 2016 | Not an RCT |
| Newbold 2017 | Pooled data from 2 trials (Bleecker 2016; FitzGerald 2016) |
| Niven 2008 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Noga 2003 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Noga 2008 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Noonan 2013 | Intervention used in study (lebrikizumab) is not anti‐IL‐5 therapy |
| Nowak 2015 | Treatment < 16 weeks |
| O'Quinn 2019 | Only pooled data (from > 1 RCT) presented |
| Oba 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Oh 2013 | Intervention used in study (anti‐IL‐9) is not anti‐IL‐5 therapy |
| Ohashi 1997 | Participants do not have a diagnosis of asthma |
| Ohman 1984 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| Ohta 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Ohta 2017 | Post hoc analysis of CALIMA (FitzGerald 2016), benralizumab study looking at the subset of patients from Japan, which is not a subgroup prespecified in our protocol |
| Ong 2005 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Ortega 2018a | Only pooled data (from > 1 RCT) presented |
| Ortega 2018b | Only pooled data (from > 1 RCT) presented |
| Panettieri 2017 | Post hoc analysis of reslizumab study looking at participants who had an FEV1 < 50%, which is not a subgroup prespecified in our analysis |
| Park 1998 | Not an RCT |
| Park 2018 | Post hoc analysis of SIROCCO (Bleecker 2016), benralizumab study looking at the subset of patients from Korea, which is not a subgroup prespecified in our protocol |
| Park 2019 | Post hoc analysis of SIROCCO (Bleecker 2016) benralizumab study looking at the subset of patients from Korea, which is not a subgroup prespecified in our protocol |
| Parker 2010 | Intervention used in study (anti‐IL‐9) is not anti‐IL‐5 therapy |
| Pauli 1984 | Intervention used in study (immunotherapy) is not anti‐IL‐5 therapy |
| Pavord 2012 | Posthoc analysis of Pavord 2012a and Ortega 2014 stratified by prior use of anti‐IgE therapy |
| Pelaia 2016 | Study is not an RCT |
| Pham 2016 | An analysis of sera collected from asthma patients enrolled in 2 clinical studies |
| Piper 2012 | Intervention used in study (tralokinumab) is not anti‐IL‐5 therapy |
| Piper 2013 | Intervention used in study (tralokinumab) is not anti‐IL‐5 therapy |
| Pouliquen 2015 | Study has no placebo arm or clinical endpoints |
| Pouliquen 2016 | Aggregation of 2 clinical trials |
| Prazma 2016 | Study is not a randomised, placebo controlled trial |
| Prieto 2006 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Pui 2010 | Intervention used in study (air/diesel exhaust +/‐ antioxidant) is not anti‐IL‐5 therapy |
| Ranade 2015 | Intervention used in study (tralokinumab) is not anti‐IL‐5 therapy |
| Rose 2009 | Intervention used in study (pneumococcal vaccine) is not anti‐IL‐5 therapy |
| Roskos 2018 | Pooled data from 2 trials (Bleecker 2016; FitzGerald 2016) |
| Roufosse 2020 | Not asthma (hypereosinophilic syndrome) |
| Sakamoto 1984 | Not an RCT |
| Scheerens 2011 | Intervention used in study (lebrikizumab) is not anti‐IL‐5 therapy |
| Scheerens 2012 | Intervention used in study (lebrikizumab) is not anti‐IL‐5 therapy |
| Scheerens 2014 | Intervention used in study (lebrikizumab) is not anti‐IL‐5 therapy |
| Shaw 2019 | Trial involves oral corticosteroid dose reduction (one of our exclusion criteria). |
| Shrimanker 2018 | Only pooled data (from > 1 RCT) presented |
| Shrimanker 2019 | Only pooled data (from > 1 RCT) presented |
| Siergiejko 2011 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Silk 1998 | Intervention used in study (pneumococcal vaccine) is not anti‐IL‐5 therapy |
| Silkoff 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Simoes 2007 | Intervention used in study (pavilizumab) is not anti‐IL‐5 therapy |
| Singh 2010 | Intervention used in study (anti‐IL‐13) is not anti‐IL‐5 therapy |
| Slavin 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Soler 2001 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Sorkness 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Steinfeld 2020 | Not asthma (hypereosinophilic syndrome) |
| Sthoeger 2007 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Sugaya 1994 | Intervention used in study (influenza vaccine) is not anti‐IL‐5 therapy |
| Swanson 2014 | Intervention used in study (dupilumab) is not anti‐IL‐5 therapy |
| Szymaniak 1998 | Not an RCT |
| Tanaka 1993 | Intervention used in study (influenza vaccine) is not anti‐IL‐5 therapy |
| Terr 1969 | Study predates monoclonal treatments |
| Vanlandingham 2019 | Only pooled data (from > 1 RCT) presented |
| Van Rensen 2009 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Vignola 2004 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Virchow 2016 | Aggregation of 2 clinical trials |
| Virchow 2017 | Only pooled data (from > 1 RCT) presented |
| Virchow 2019 | Only pooled data (from > 1 RCT) presented |
| Virchow 2020 | Only pooled data (from > 1 RCT) presented |
| Virchow 2020a | Only pooled data (from >1 RCT) presented |
| Wang 2015 | Pharmacometrics assessment of phase IIb data to characterise the exposure‐response relationship with benralizumab in adults with asthma |
| Wang 2017 | Only pooled data (from > 1 RCT) presented |
| Wark 2003 | Intervention used in study (itraconazole) is not anti‐IL‐5 therapy |
| Wechsler 2017 | Pooled data from 2 trials (Castro 2015a; Castro 2015b) |
| Wechsler 2017a | Only pooled data (from > 1 RCT) presented |
| Wechsler 2019 | Only pooled data (from > 1 RCT) presented |
| Wechsler 2020 | Post hoc analysis of reslizumab studies looking at participants who had ≥ 2 or ≥ 3 exacerbations, which is not a subgroup prespecified in our analysis |
| Weinstein 2016 | Combined secondary analysis of 2 trials |
| Wenzel 2009 | Intervention used in study (golimumab) is not anti‐IL‐5 therapy |
| Wenzel 2013 | Interventionused in study (dupilumab) is not anti‐IL‐5 therapy |
| Wenzel 2013a | Intervention used in study (dupilumab) is not anti‐IL‐5 therapy |
| Wenzel 2014 | Intervention used in study (dupilumab) is not anti‐IL‐5 therapy |
| Xu 2017 | Pooled data from 2 trials (Bleecker 2016; FitzGerald 2016) |
| Xu 2018 | Pooled data from 2 trials (Bleecker 2016; FitzGerald 2016) |
| Yan 2015 | Participants do not have a diagnosis of asthma |
| Yancey 2017 | Analysis of subgroup not relevant to our protocol (participants with ≥ 3 exacerbations and eosinophils ≥ 300/μL) |
| Yancey 2020 | Analysis of subgroup not relevant to our protocol |
| Zangrilli 2019 | Pooled data from 2 trials (Bleecker 2016; FitzGerald 2016) |
| Zetterstrom 1972 | Participants do not all have diagnosis of asthma |
| Zhu 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
| Zielen 2013 | Intervention used in study (omalizumab) is not anti‐IL‐5 therapy |
COPD: chronic obstructive pulmonary disease; FeNO: exhaled fraction of nitric oxide; IV: intravenous; OCS: oral corticosteroid; RCT: randomised controlled trial; SC: subcutaneous